<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250210</url>
  </required_header>
  <id_info>
    <org_study_id>ATI-CL11</org_study_id>
    <nct_id>NCT01250210</nct_id>
  </id_info>
  <brief_title>Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control</brief_title>
  <official_title>Evaluation of Pharmacodynamic Effects on Ovulation Suppression and Cycle Control of Three Agile Contraceptive Patches Containing Different Doses of Ethinyl Estradiol(EE)During Three Cycles of Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agile Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agile Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the adequacy of ovulation suppression, cycle control, and safety of three
      transdermal contraceptive delivery systems (TCDSs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective was to evaluate the adequacy of ovulation suppression, cycle control,
      and safety of three transdermal contraceptive delivery systems (TCDSs) containing 2 different
      doses of levonorgestrel (LNG) and 3 different doses of ethinyl estradiol (EE) during 3
      consecutive cycles of administration of each treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovulation Suppression in Three Treatment Groups Over 3 Cycles</measure>
    <time_frame>3 months</time_frame>
    <description>Ovulation suppression measured by possible ovulation. Possible ovulation is defined as cycles with greatest progesterone level ≥4.7 ng/mL across Cycles 1-3 combined for each Arm/Group. The following four primary analysis datasets are:
Intent-to-treat (ITT): At least 1 study patch was applied and at least 1 progesterone measurement is available at 1 of the nominal data collection points.
Complete progesterone: At least 1 study patch was applied and at least 3 progesterone measurements are available across any of the data collection points.
Perfect compliance: If no patch has been off &gt;1 day and no more than 1 day has elapsed between patch changes.
Verifiable compliance: is a cycle during which at least 1 study patch was applied and where LNG and EE measurements were available at each of the nominal data collection points of Days 8, 15, and 22, and all values were above the lower detection limit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cycle Control</measure>
    <time_frame>3 months</time_frame>
    <description>The incidence of breakthrough bleeding (BTB) and/or spotting (S) episodes in Cycle 3 for ITT cycles. A BTB/S episode was defined as any number of days with BTB and/or BTS preceded and followed by at least 2 bleeding-free days.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Ovulation Suppression</condition>
  <arm_group>
    <arm_group_label>AG200-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug intervention with levonorgestrel and ethinyl estradiol : AG200-15 a transdermal contraceptive system containing 2.60 mg of levonorgestrel and 2.30 mg of ethinyl estradiol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AG200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug intervention with levonorgestrel and ethinyl estradiol: AG200 a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.92 of ethinyl estradiol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AG200LE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug intervention with levonorgestrel and ethinyl estradiol: AG200LE a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.28 mg of ethinyl estradiol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levonorgestrel and ethinyl estradiol</intervention_name>
    <description>pregnancy prevention</description>
    <arm_group_label>AG200</arm_group_label>
    <arm_group_label>AG200-15</arm_group_label>
    <arm_group_label>AG200LE</arm_group_label>
    <other_name>contraception</other_name>
    <other_name>hormonal contraception</other_name>
    <other_name>transdermal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult women, ages 18-45.

          2. Cycles with a usual duration between 21 and 35 days and an individual variation of +/
             3 days.

          3. Normotensive (blood pressure &lt; 140/90 mm Hg at rest) at screening and randomization
             visits (Visits 1 and 2).

          4. Willing to use a non-hormonal method of contraception for the entire duration of the
             study, or

          5. Have already undergone previous bilateral tubal ligation OR vasectomized partner OR
             not at risk of pregnancy.

          6. Willing to refrain from excessive use of alcohol during the entire duration of the
             study.

          7. Willing to give informed consent to participate in the study.

        Exclusion Criteria:

          1. History of significant medical illness or seizures.

          2. Positive hepatitis B or C antibody or positive human immunodeficiency virus (HIV)
             antibody.

          3. Known or suspected pregnancy.

          4. A recent abnormal cervical smear - low-grade squamous intraepithelial lesion (SIL) or
             higher in the Bethesda System - which has not been resolved or treated.

          5. Any disorder that contraindicates the use of contraceptive steroids i.e., history of
             heart attack and stroke, blood clots in the legs, lungs or eyes, history of blood
             clots in the deep veins of the legs, known or suspected breast cancer, hepatitis or
             yellowing of the whites of the eyes or the skin (jaundice) during pregnancy or during
             previous use of hormonal contraceptives, headaches with neurological symptoms, disease
             of heart valves with complications.

          6. Uncontrolled thyroid disorder.

          7. History of or existing thromboembolic disorder, vascular disease, cerebral vascular,
             or coronary artery disease.

          8. Undiagnosed abnormal genital bleeding.

          9. Known or suspected breast carcinoma, endometrial carcinoma, or estrogen-dependent
             neoplasia.

         10. History or presence of dermal hypersensitivity in response to topical application.

         11. Use of an injectable hormonal contraceptive (e.g. Depo-Provera®) within 6 months prior
             to Day 1.

         12. Use of a contraceptive implant (e.g. Implanon® or Jadelle®) or hormone-medicated
             intrauterine device within 2 months (60 days) prior to Day 1.

         13. Use of OCs or other sex steroid hormones within 60 days prior to Day 1.

         14. Women who are breast-feeding or are within 2 months of stopping breast-feeding.

         15. Status post-partum or post-abortion within a period of 2 months prior to Day 1.

         16. Chronic use of any medication that might interfere with the metabolism of hormone
             contraceptives (e.g., rifampin, barbiturates, phenytoin, primidone, topiramate,
             carbamazepine, phenylbutazone, ritonavir, modafinil, St John's Wort etc.) or use
             within the past 3 months prior to Day 1.

         17. Administration of investigational drug within 30 days prior to Day 1.

         18. A history (within prior 12 months) of drug or alcohol abuse.

         19. Women who smoke more than 4-5 cigarettes daily.

         20. History of skin sensitivity to adhesives.

         21. Use of over-the-counter medications or herbals that might interfere with the
             metabolism of hormone contraceptives within 3 days prior to wearing the first patch.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Garner, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Agile Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <results_first_submitted>January 22, 2013</results_first_submitted>
  <results_first_submitted_qc>July 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2018</results_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contraception</keyword>
  <keyword>pregnancy prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Planned enrollment included: approximately 30 subjects in the AG200LE treatment group, 30 subjects in the AG200 treatment group and 20 to 30 subjects in the AG200 15 treatment group. Actual enrollment included: 45 subjects in the AG200 treatment group; 45 subjects in the AG200LE treatment group; and 33 subjects in the AG200-15 treatment group.</recruitment_details>
      <pre_assignment_details>: Subjects enrolled were healthy adult women aged 18-45 years with a history of regular menstrual cycles (i.e., lasting between 21 and 35 days) and no disorders precluding hormonal contraceptive use.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AG200LE Transdermal Contraceptive Delivery System</title>
          <description>a 12.5 cm2 patch (Lot #27621) containing 2.17 LNG/1.28 EE mg (designed to deliver approximately: 0.075 LNG/0.015 EE mg/day).</description>
        </group>
        <group group_id="P2">
          <title>AG200 Transdermal Contraceptive Delivery System</title>
          <description>a 12.5 cm2 patch (Lot #27620) containing 2.17 LNG/1.92 EE mg (designed to deliver approximately: 0.1 LNG/0.02 EE mg/day).</description>
        </group>
        <group group_id="P3">
          <title>AG200-15 Transdermal Contraceptive System</title>
          <description>a 15 cm2 patch (Lot #27620) containing 2.60 LNG/2.30 EE mg (designed to deliver approximately: 0.12 LNG/0.025 EE mg/day).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>AG200LE Transdermal Contraceptive Delivery System</title>
          <description>a 12.5 cm2 patch (Lot #27621) containing 2.17 LNG/1.28 EE mg (designed to deliver approximately: 0.075 LNG/0.015 EE mg/day).</description>
        </group>
        <group group_id="B2">
          <title>AG200 Transdermal Contraceptive Delivery System</title>
          <description>a 12.5 cm2 patch (Lot #27620) containing 2.17 LNG/1.92 EE mg (designed to deliver approximately: 0.1 LNG/0.02 EE mg/day).</description>
        </group>
        <group group_id="B3">
          <title>AG200-15 Transdermal Contraceptive System</title>
          <description>a 15 cm2 patch (Lot #27620) containing 2.60 LNG/2.30 EE mg (designed to deliver approximately: 0.12 LNG/0.025 EE mg/day).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="7.4"/>
                    <measurement group_id="B2" value="31" spread="6.9"/>
                    <measurement group_id="B3" value="32.1" spread="7.8"/>
                    <measurement group_id="B4" value="31.6" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ovulation Suppression in Three Treatment Groups Over 3 Cycles</title>
        <description>Ovulation suppression measured by possible ovulation. Possible ovulation is defined as cycles with greatest progesterone level ≥4.7 ng/mL across Cycles 1-3 combined for each Arm/Group. The following four primary analysis datasets are:
Intent-to-treat (ITT): At least 1 study patch was applied and at least 1 progesterone measurement is available at 1 of the nominal data collection points.
Complete progesterone: At least 1 study patch was applied and at least 3 progesterone measurements are available across any of the data collection points.
Perfect compliance: If no patch has been off &gt;1 day and no more than 1 day has elapsed between patch changes.
Verifiable compliance: is a cycle during which at least 1 study patch was applied and where LNG and EE measurements were available at each of the nominal data collection points of Days 8, 15, and 22, and all values were above the lower detection limit.</description>
        <time_frame>3 months</time_frame>
        <population>ITT, perfect compliance, complete progesterone, verifiable compliance</population>
        <group_list>
          <group group_id="O1">
            <title>AG200LE</title>
            <description>a 12.5 cm2 patch (Lot #27621) containing 2.17 LNG/1.28 EE mg (designed to deliver approximately: 0.075 LNG/0.015 EE mg/day).</description>
          </group>
          <group group_id="O2">
            <title>AG200</title>
            <description>a 12.5 cm2 patch (Lot #27620) containing 2.17 LNG/1.92 EE mg (designed to deliver approximately: 0.1 LNG/0.02 EE mg/day).</description>
          </group>
          <group group_id="O3">
            <title>AG200-15</title>
            <description>a 15 cm2 patch (Lot #27620) containing 2.60 LNG/2.30 EE mg (designed to deliver approximately: 0.12 LNG/0.025 EE mg/day).</description>
          </group>
        </group_list>
        <measure>
          <title>Ovulation Suppression in Three Treatment Groups Over 3 Cycles</title>
          <description>Ovulation suppression measured by possible ovulation. Possible ovulation is defined as cycles with greatest progesterone level ≥4.7 ng/mL across Cycles 1-3 combined for each Arm/Group. The following four primary analysis datasets are:
Intent-to-treat (ITT): At least 1 study patch was applied and at least 1 progesterone measurement is available at 1 of the nominal data collection points.
Complete progesterone: At least 1 study patch was applied and at least 3 progesterone measurements are available across any of the data collection points.
Perfect compliance: If no patch has been off &gt;1 day and no more than 1 day has elapsed between patch changes.
Verifiable compliance: is a cycle during which at least 1 study patch was applied and where LNG and EE measurements were available at each of the nominal data collection points of Days 8, 15, and 22, and all values were above the lower detection limit.</description>
          <population>ITT, perfect compliance, complete progesterone, verifiable compliance</population>
          <units>%of cycles with possible ovulation</units>
          <param>Number</param>
          <units_analyzed>Total number of cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total number of cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ITT, perfect compliance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5"/>
                    <measurement group_id="O2" value="20.7"/>
                    <measurement group_id="O3" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete progesterone, perfect compliance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9"/>
                    <measurement group_id="O2" value="20.7"/>
                    <measurement group_id="O3" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT, verifiable compliance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete progesterone, verifiable compliance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cycle Control</title>
        <description>The incidence of breakthrough bleeding (BTB) and/or spotting (S) episodes in Cycle 3 for ITT cycles. A BTB/S episode was defined as any number of days with BTB and/or BTS preceded and followed by at least 2 bleeding-free days.</description>
        <time_frame>3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>AG200LE</title>
            <description>a 12.5 cm2 patch (Lot #27621) containing 2.17 LNG/1.28 EE mg (designed to deliver approximately: 0.075 LNG/0.015 EE mg/day).</description>
          </group>
          <group group_id="O2">
            <title>AG200</title>
            <description>a 12.5 cm2 patch (Lot #27620) containing 2.17 LNG/1.92 EE mg (designed to deliver approximately: 0.1 LNG/0.02 EE mg/day).</description>
          </group>
          <group group_id="O3">
            <title>AG200-15</title>
            <description>a 15 cm2 patch (Lot #27620) containing 2.60 LNG/2.30 EE mg (designed to deliver approximately: 0.12 LNG/0.025 EE mg/day).</description>
          </group>
        </group_list>
        <measure>
          <title>Cycle Control</title>
          <description>The incidence of breakthrough bleeding (BTB) and/or spotting (S) episodes in Cycle 3 for ITT cycles. A BTB/S episode was defined as any number of days with BTB and/or BTS preceded and followed by at least 2 bleeding-free days.</description>
          <population>ITT population</population>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.46"/>
                    <measurement group_id="O2" value="0.29" spread="0.46"/>
                    <measurement group_id="O3" value="0.15" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse Events were analyzed for the Safety population. Adverse Events analyzed are based on Organ System class only.</desc>
      <group_list>
        <group group_id="E1">
          <title>AG200LE</title>
          <description>a 12.5 cm2 patch (Lot #27621) containing 2.17 LNG/1.28 EE mg (designed to deliver approximately: 0.075 LNG/0.015 EE mg/day).</description>
        </group>
        <group group_id="E2">
          <title>AG200</title>
          <description>a 12.5 cm2 patch (Lot #27620) containing 2.17 LNG/1.92 EE mg (designed to deliver approximately: 0.1 LNG/0.02 EE mg/day).</description>
        </group>
        <group group_id="E3">
          <title>AG200-15</title>
          <description>a 15 cm2 patch (Lot #27620) containing 2.60 LNG/2.30 EE mg (designed to deliver approximately: 0.12 LNG/0.025 EE mg/day).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All publications must be reviewed and approved by sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Chiodo III, Senior Medical Director</name_or_title>
      <organization>Agile Therapeutics</organization>
      <phone>609-683-1880</phone>
      <email>jachiodo@agiletherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

